Tissue Regenix Group PLC Result of General Meeting and Total Voting Rights (4288P)
June 09 2020 - 8:10AM
UK Regulatory
TIDMTRX
RNS Number : 4288P
Tissue Regenix Group PLC
09 June 2020
Tissue Regenix Group plc
Result of General Meeting
and
Total voting rights
Leeds, 9 June 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix", the "Company" or the "Group"), is pleased to announced
that at a General Meeting held earlier today, all Resolutions as
set out in the Circular and Notice of General Meeting dated 22 May,
were duly passed by shareholders. Defined terms referred to in this
announcement have the meaning given in the Circular and Notice of
General Meeting dated 22 May.
Application has been made for the 5,859,626,212 new Ordinary
Shares issued pursuant to the recent fundraising (comprised of the
4,811,626,212 Placing Shares, 800,000,000 PrimaryBid Shares,
248,000,000 Subscription Shares and an additional 11,600,000 new
Ordinary Shares issued pursuant to the Company's existing
authorities), (together the "Fundraising Shares") to be admitted to
trading on AIM. It is anticipated that trading will commence at 8am
on 10 June 2020.
Gareth Jones, Interim CEO, Tissue Regenix Group: "We are pleased
to have received shareholder approval for this fundraise. This
investment will allow us to implement our capacity expansion
programme and support the development of the Group as we look to
scale our operations to address additional market
opportunities."
The results of the polls are set out below:
Resolution Votes % Votes against % of Votes cast Total Votes
for of votes in total votes withheld
votes cast cast
cast as
a %
of
issued
share
capital
Authorise the
Directors under
section 551 of
the Companies
Act 2006 to allot
the New Ordinary
Shares 583,293,491 97.95 12,195,653 2.05 595,489,144 50.81 508,081
------------ ------- -------------- ------- ------------ --------- ----------
Authorise the
Directors to
subdivide the
1,171,971,322
Ordinary Shares
of 0.5 pence
in the capital
of the Company
into 1,171,971,322
Ordinary Shares
of 0.1 pence
and 1,171,971,322
Deferred Shares
of 0.4 pence
in the capital
of the Company 583,293,491 97.95 12,195,653 2.05 595,489,144 50.81 508,081
------------ ------- -------------- ------- ------------ --------- ----------
Special resolution
to amend the
articles of association 583,293,491 97.95 12,195,653 2.05 595,489,144 50.81 508,081
------------ ------- -------------- ------- ------------ --------- ----------
Special resolution
to authorise
the Directors
under section
570 of the Companies
Act 2006, to
allot the New
Ordinary Shares
pursuant to the
Fundraising on
a non-pre-emptive
basis. 583,307,442 97.95 12,181,702 2.05 595,489,144 50.81 508,081
------------ ------- -------------- ------- ------------ --------- ----------
Total voting rights
Following admission of the Fundraising Shares the number of
Ordinary Shares of 0.1 pence in issue and number of voting rights
will be 7,031,597,534 . The above figure may be used by
shareholders as the denominator for the calculations by which they
will determine whether they are required to notify their interest
in, or a change to their interest in, the Company under the
Financial Conduct Authority's Disclosure and Transparency
Rules.
For more Information:
Tissue Regenix Group plc Tel: 0330 430
Caitlin Pearson, Head of Communications 3073
--------------------------------------------- ---------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710
Adviser and Broker) 7600
Jonathan Senior / Alex Price / Ben Maddison
--------------------------------------------- ---------------
FTI Consulting Tel: 0203 727
Simon Conway / Victoria Foster Mitchell 1000
/ Mary Whittow
============================================= ===============
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMEAAKNEEEEEFA
(END) Dow Jones Newswires
June 09, 2020 08:10 ET (12:10 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024
